focu shift i/o approach
syndax report earn provid busi updat
investor focu turn data earlier-stag i/o
pipelin although key phase readout lead program entinostat
exemestan advanc hr breast cancer come view
previous ascrib chanc success street seem
less optimist interim look forward updat asco
abstract releas includ present phase data
pretreat nsclc melanoma initi stage data nave mss-crc
target respons rate respect revis
opex estim remain bullish
final analysi releas ecog-acrin
enrol complet enrol previous disclos
os event occur first interim ecog
provid updat event rate protocol also call futil analys
os interv may/novemb
data full phase melanoma cohort
guid updat registr strategi entinostat
indic mid-year expect focu patient fail
initi cohort given clearer regulatori path
increas use therapi melanoma
mss-crc cohort initi data present
howev sndx/merck announc new target respons rate
result modif studi design base kol feedback bar
clinic relev go/no-go decis stage ii push
requir respons patient enrol
also present phase data nsclc cohort
increasingli focus enrich pretreat patient
popul futur studi use biomarker-driven strategi treatment
landscap nsclc evolv comprehens biomark work earli stage
on-going across entinostat indic
updat rest pipelin slate
beyond
phase data tnbc ovarian expect
mad studi on-going phase imfinzi also initi patient
data present menin-mllr ind file compani
substanti clinic activ on-going opex burn accord
develop entinostat
multipl cancer
current
trial exemestan
ph
treatment hr breast
cancer earli stage trial
combin entinostat
lung melanoma tnbc ovarian
analyst certif import disclosur see disclosur
entinostat demonstr benefit phase studi
line phase result
entinostat demonstr encourag clinic go/no-go result
immuno-oncolog trial variou inhibitor
partnership remain intact syndax continu develop
addit indic entinostat combin
syndax develop entinostat class hdac inhibitor
treatment solid tumor believ share
time reflect opportun entinostat advanc
er breast cancer current pivot phase trial
also broad benefit epigenet immuno-modulatori
therapi entinostat abil combin therapi
across rang tumor type believ underappreci
encor entinostat phase data pre-tx
melanoma nsclc stage mss-crc data
announc registr strategi entinostat melanoma
complet phase enrol releas ecog
entinostat go/no-go decis stage
mss-crc cohort report tnbc oc data file
ind menin mllr program
phase os interim futil analys
phase trial demonstr os benefit entinostat
exemestan hr breast cancer creat new standard
care indic
meet endpoint entinostat approv
acceler basi
entinostat demonstr profound result immuno-oncolog trial
remain leader clinic hdac/io combin trial
phase trial stop interim due failur demonstr
os benefit entinostat exemestan hr
entinostat fail confer benefit any/few hdac/io combo trial
competitor hdac inhibitor approach move faster
anticip clinic trial
valu entinostat hr her- breast cancer appli typic multipl estim ww sale
second-lin hr discount annual assum probabl market valu earli stage entinostat i/o clinic trial
assum probabl market sale earli stage cash make
valuat
trade risk
financi result project thousand except per share data us incom total revenu good gener total expens oper incom interest expens expens incom incom tax net incom gaap net incom gaap basic ep gaap dilut ep weight share dilut share syndax pharmaceut
stock price compani mention report
